Srikala S Sridhar

Srikala S Sridhar

UNVERIFIED PROFILE

Are you Srikala S Sridhar?   Register this Author

Register author
Srikala S Sridhar

Srikala S Sridhar

Publications by authors named "Srikala S Sridhar"

Are you Srikala S Sridhar?   Register this Author

95Publications

2893Reads

32Profile Views

Impact of age at diagnosis of de novo metastatic prostate cancer on survival.

Cancer 2020 Mar 26;126(5):986-993. Epub 2019 Nov 26.

Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32630DOI Listing
March 2020

Is it time to redefine cisplatin ineligibility in metastatic urothelial cancer?

Eur J Cancer 2020 Mar 31;127:158-159. Epub 2020 Jan 31.

Princess Margaret Cancer Center, University of Toronto, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.12.019DOI Listing
March 2020

Trimodality Therapy for Muscle-Invasive Bladder Cancer: Recent Advances and Unanswered Questions.

Curr Oncol Rep 2020 Feb 1;22(2):14. Epub 2020 Feb 1.

Department of Medicine, Division of Medical Oncology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Canada, 700 University Avenue, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-020-0880-5DOI Listing
February 2020

Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer.

Urol Oncol 2020 Feb 11. Epub 2020 Feb 11.

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Departments of Urology, Weill Cornell Medical College, New York, New York; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2020.01.010DOI Listing
February 2020

Balancing efficacy and financial toxicity in the management of metastatic castration-sensitive prostate cancer.

Can Urol Assoc J 2019 Dec;13(12):404-405

Princess Margaret Cancer Centre, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5489/cuaj.6346DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892692PMC
December 2019

Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer.

Oncotarget 2019 Apr 26;10(31):2947-2958. Epub 2019 Apr 26.

Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26893DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6508206PMC
April 2019

Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.

Clin Genitourin Cancer 2019 Feb 4;17(1):38-45. Epub 2018 Oct 4.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2018.09.021DOI Listing
February 2019

Prime time for immunotherapy in advanced urothelial cancer.

Asia Pac J Clin Oncol 2018 Nov;14 Suppl 5:24-32

Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.13059DOI Listing
November 2018

The Bladder Utility Symptom Scale: A Novel Patient Reported Outcome Instrument for Bladder Cancer.

J Urol 2018 08 9;200(2):283-291. Epub 2018 Mar 9.

Division of Urology, Department of Surgery (NP, AF, RG, GK), University of Toronto and University Health Network, Toronto, Ontario, Canada; Toronto Health Economics and Technology Assessment Collaborative (MDK, KEBo, KEBr), University of Toronto and University Health Network, Toronto, Ontario, Canada; Division of Internal Medicine and Geriatrics (MDK, SMHA), University of Toronto and University Health Network, Toronto, Ontario, Canada; Department of Medical Oncology (SSS), University of Toronto and University Health Network, Toronto, Ontario, Canada; Department of Radiation Oncology (PC), University of Toronto and University Health Network, Toronto, Ontario, Canada; University Health Network and Toronto General Research Institute (GT), Toronto, Ontario, Canada; Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Division of Urology, Trillium Health Partners (MJ), Mississauga, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2018.03.006DOI Listing
August 2018

Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis.

Cancer 2018 06 6;124(12):2507-2514. Epub 2018 Apr 6.

Department of Urology, The Ohio State University, Columbus, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31372DOI Listing
June 2018

Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies.

Clin Genitourin Cancer 2017 Sep 8. Epub 2017 Sep 8.

Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673173027
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2017.08.019DOI Listing
September 2017

Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.

J Clin Oncol 2017 Jul 14;35(20):2299-2305. Epub 2017 Apr 14.

Girish S. Kulkarni, Thomas Hermanns, Yanliang Wei, Bimal Bhindi, Raj Satkunasivam, Paul Athanasopoulos, Peter J. Bostrom, Kathy Li, Arnoud J. Templeton, Srikala S. Sridhar, Peter Chung, Robert G. Bristow, Michael Milosevic, Padraig Warde, Neil E. Fleshner, Michael A.S. Jewett, Shaheena Bashir, and Alexandre R. Zlotta, Princess Margaret Cancer Center, University Health Network, University of Toronto; Cynthia Kuk and Alexandre R. Zlotta, Mount Sinai Hospital, University of Toronto; Theodorus H. Van Der Kwast, University Health Network, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.2327DOI Listing
July 2017

Evolving Treatment of Advanced Urothelial Cancer.

J Oncol Pract 2017 05;13(5):309-315

Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2017.022137DOI Listing
May 2017

Complete Responses with Targeted Therapy in Metastatic Renal Cell Carcinoma: Balancing Efficacy and Toxicity.

Eur Urol 2016 09 9;70(3):476-7. Epub 2016 Feb 9.

Princess Margaret Cancer Center, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2016.01.050DOI Listing
September 2016

Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.

Breast J 2015 Nov-Dec;21(6):658-64. Epub 2015 Sep 20.

Medical Oncology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/tbj.12501DOI Listing
August 2016

It Is Time to Harmonize the Design and Conduct of Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer.

Eur Urol 2016 08 9;70(2):263-4. Epub 2015 Dec 9.

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2015.11.025DOI Listing
August 2016

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.

J Clin Oncol 2016 05 29;34(13):1500-9. Epub 2016 Feb 29.

Daniel P. Petrylak, Yale University Cancer Center, New Haven, CT; Scott T. Tagawa, Weill Cornell Medical College, New York; David Shaffer, New York Oncology Hematology, Albany, NY; Manish Kohli, Mayo Clinic, Rochester, MN; Andrea Eisen, Sunnybrook Health Sciences Centre; Srikala S. Sridhar, Princess Margaret Hospital, Toronto; Christina Canil, Ottawa Hospital Cancer Centre, Ottawa, Ontario; Kim N. Chi, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Alexander Spira, Virginia Cancer Specialists, Fairfax, VA; Alexander Spira, John M. Burke, David Shaffer, and Nicholas J. Vogelzang, US Oncology Research, The Woodlands, TX; Evan Y. Yu, University of Washington Medical Center and Fred Hutchinson Cancer Research Center, Seattle, WA; John M. Burke, Rocky Mountain Cancer Centers, Aurora, CO; Chong-Xian Pan, University of California-Davis Medical Center, Sacramento; David I. Quinn, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Jenny J. Kim, Johns Hopkins University, Baltimore, MD; Jeanny B. Aragon-Ching, George Washington University Medical Center, Washington, DC; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Shande Tang, Hui Zhang, Christopher T. Cavanaugh, Ling Gao, and John S. Kauh, Eli Lilly, Bridgewater, NJ; and Richard A. Walgren, Eli Lilly, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.0218DOI Listing
May 2016

Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.

Prostate 2016 Feb 2;76(2):235-42. Epub 2015 Nov 2.

Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23117DOI Listing
February 2016

Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy.

Br J Cancer 2016 Jan 10;114(2):207-12. Epub 2015 Dec 10.

Division of Urology, Department of Surgery, University Health Network, University of Toronto, 610 University Avenue, Toronto, Ontario M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2015.432DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815810PMC
January 2016

Options in metastatic urothelial cancer after first-line therapy.

Curr Opin Support Palliat Care 2015 Sep;9(3):255-60

aTom Baker Cancer Center, Calgary, Alberta, Canada bPrincess Margaret Cancer Center, University of Toronto 5-222, 610 University Avenue, Toronto, ON M5G 6M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/SPC.0000000000000158DOI Listing
September 2015

Neutrophil-Lymphocyte Ratio and Pathological Response to Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer.

Clin Genitourin Cancer 2015 Aug 7;13(4):e229-e233. Epub 2015 Feb 7.

Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2015.02.001DOI Listing
August 2015

Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer.

J Geriatr Oncol 2015 Jan 7;6(1):23-8. Epub 2014 Oct 7.

Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2014.09.183DOI Listing
January 2015

Practice patterns and perceptions of survivorship care in Canadian genitourinary oncology: A multidisciplinary perspective.

Can Urol Assoc J 2014 Nov;8(11-12):409-17

Departments of Surgery (Urology) and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5489/cuaj.2279DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277520PMC
November 2014

Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone.

Prostate 2014 Oct 11;74(14):1462-4. Epub 2014 Aug 11.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.22861DOI Listing
October 2014

The importance of surgeon characteristics on impacting oncologic outcomes for patients undergoing radical cystectomy.

J Urol 2014 Sep 1;192(3):714-9. Epub 2014 Mar 1.

Division of Urology, Department of Surgery, University Health Network, University of Toronto, Toronto, Ontario, Canada; Institute for Clinical and Evaluative Sciences, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2014.02.093DOI Listing
September 2014

Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole.

Eur J Cancer 2014 Sep 16;50(14):2399-407. Epub 2014 Jul 16.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Center, University Health Network, Toronto, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2014.06.004DOI Listing
September 2014

Castration-resistant prostate cancer: from new pathophysiology to new treatment.

Eur Urol 2014 Feb 11;65(2):289-99. Epub 2013 Aug 11.

University of Montreal Hospital Center, Montreal, PQ, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2013.08.008DOI Listing
February 2014

A case of isolated rectal recurrence of muscle invasive bladder cancer.

Can Urol Assoc J 2013 May-Jun;7(5-6):E376-80

Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5489/cuaj.1223DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3668414PMC
June 2013

Impact of Age at Diagnosis on Outcomes in Men with Castrate-Resistant Prostate Cancer (CRPC).

J Cancer 2013 21;4(4):304-14. Epub 2013 Mar 21.

1. Division of Medical Oncology, British Columbia Cancer Agency, Vernon, BC, Canada;

View Article

Download full-text PDF

Source
http://www.jcancer.org/v04p0304.pdf
Web Search
http://www.jcancer.org/v04p0304.htm
Publisher Site
http://dx.doi.org/10.7150/jca.4192DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619091PMC
April 2013

Efficacy and tolerability of lapatinib in the management of breast cancer.

Breast Cancer (Auckl) 2012 7;6:67-77. Epub 2012 Mar 7.

Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4137/BCBCR.S6374DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306225PMC
August 2012

New directions for biologic targets in urothelial carcinoma.

Mol Cancer Ther 2012 Jun 9;11(6):1226-35. Epub 2012 May 9.

Department of Medical Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-11-0756DOI Listing
June 2012

A case of metastatic urachal adenocarcinoma treated with several different chemotherapeutic regimens.

Can Urol Assoc J 2012 Feb;6(1):E27-31

Medical Oncologist, Assistant Professor, Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5489/cuaj.11109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3289708PMC
February 2012

A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium.

Invest New Drugs 2011 Oct 27;29(5):1045-9. Epub 2010 Feb 27.

Princess Margaret Hospital, Phase II Consortium, 610 University Avenue, Suite 5-222, Toronto, Ontario M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10637-010-9408-4
Publisher Site
http://dx.doi.org/10.1007/s10637-010-9408-4DOI Listing
October 2011

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer.

Cancer Chemother Pharmacol 2011 Apr 3;67(4):927-33. Epub 2010 Jul 3.

Princess Margaret Hospital, Phase II Consortium, University of Toronto, 610 University Avenue, Suite 5-222, Toronto, ON M5G 2M9, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-010-1389-7DOI Listing
April 2011

Notch signaling pathway as a therapeutic target in breast cancer.

Mol Cancer Ther 2011 Jan 22;10(1):9-15. Epub 2010 Oct 22.

University of Toronto, Princess Margaret Hospital, 610 University Avenue, Suite 5-222, Toronto, Ontario, M5G 2M9.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-10-0677DOI Listing
January 2011

Health-related quality of life in cancer patients--more answers but many questions remain.

J Natl Cancer Inst 2009 Jun 9;101(12):838-9. Epub 2009 Jun 9.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djp140DOI Listing
June 2009

Insulin-insulin-like growth factor axis and colon cancer.

J Clin Oncol 2009 Jan 8;27(2):165-7. Epub 2008 Dec 8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.19.8937DOI Listing
January 2009

A case of small bowel obstruction due to intraluminal metastases from metastatic renal cell cancer.

Oncologist 2008 Feb;13(2):95-7

Department of Medicine, Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2006-0214DOI Listing
February 2008

Raf kinase as a target for anticancer therapeutics.

Mol Cancer Ther 2005 Apr;4(4):677-85

Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Avenue, Suite 5-210, Toronto, Ontario, Canada M5G 2M9.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-04-0297DOI Listing
April 2005

Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer.

Lung Cancer 2003 Dec;42 Suppl 1:S81-91

Department of Medicine, Division of Hematology Oncology of the University Health Network, Princess Margaret Hospital Division, and the University of Toronto, 610 University Avenue, Suite 5-104, Toronto, ON, Canada M5G 2M9.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0169-5002(03)00308-8DOI Listing
December 2003

Angiogenesis inhibitors under study for the treatment of lung cancer.

Lung Cancer 2003 Aug;41 Suppl 1:S63-72

Division of Hematology Oncology, Department of Medicine, University Health Network, Princess Margaret Hospital Division, University of Toronto, 610 University Avenue, Suite 5-104, Ont., M5G 2M9, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0169-5002(03)00144-2DOI Listing
August 2003

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer.

Lancet Oncol 2003 Jul;4(7):397-406

Division of Medical Oncology, Department of Medicine of the University Health Network, Princess Margaret Hospital and the University of Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1470-2045(03)01137-9DOI Listing
July 2003